{"id":84832,"date":"2026-05-29T10:06:38","date_gmt":"2026-05-29T10:06:38","guid":{"rendered":"https:\/\/www.cofb.org\/?p=84832"},"modified":"2026-05-29T10:06:40","modified_gmt":"2026-05-29T10:06:40","slug":"la-farmacia-es-mulla-per-lesclerosi-multiple-situacio-actual-opcions-terapeutiques-i-casos-practics","status":"publish","type":"post","link":"https:\/\/www.cofb.org\/ca\/2026\/05\/29\/la-farmacia-es-mulla-per-lesclerosi-multiple-situacio-actual-opcions-terapeutiques-i-casos-practics\/","title":{"rendered":"La farm\u00e0cia es mulla per l\u2019esclerosi m\u00faltiple: situaci\u00f3 actual, opcions terap\u00e8utiques i casos pr\u00e0ctics"},"content":{"rendered":"\n

El Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB) va acollir la sessi\u00f3 formativa \u201cLa farm\u00e0cia es mulla per l’esclerosi m\u00faltiple: situaci\u00f3 actual, opcions terap\u00e8utiques i casos pr\u00e0ctics\u201d<\/strong>, coorganitzada amb la Fundaci\u00f3 Esclerosi M\u00faltiple (FEM)<\/a>. La confer\u00e8ncia, moderada per Miquel Recasens<\/strong>, tresorer i responsable de la Comissi\u00f3 de Comprom\u00eds Social del COFB, va comptar amb la participaci\u00f3 de Rosa Masriera<\/strong>, directora de la FEM; el Dr. Xavier Montalban<\/strong>, president del Centre d’Esclerosi M\u00fatiple de Catalunya (Cemcat) i vicepresident de la FEM; Miguel Robles<\/strong>, infermer cl\u00ednic al Cemcat; i el testimoni d’Enric Riera<\/strong>, pacient amb esclerosi m\u00faltiple.<\/p>\n\n\n\n

\"D'esquerra<\/a>
D’esquerra a dreta: Miguel Robles, el Dr. Xavier Montalban, Rosa Masriera, Miquel Recasens i Enric Riera. <\/figcaption><\/figure>\n\n\n\n

L\u2019objectiu de la jornada era actualitzar els coneixements dels farmac\u00e8utics sobre una patologia cr\u00f2nica i complexa on la farm\u00e0cia comunit\u00e0ria \u00e9s un punt clau per a l\u2019acompanyament i la millora de l\u2019adher\u00e8ncia terap\u00e8utica<\/strong>.<\/p>\n\n\n\n

Estrat\u00e8gia terap\u00e8utica davant la malaltia<\/strong><\/h2>\n\n\n\n

El Dr. Xavier Montalban<\/strong> va abordar l\u2019evoluci\u00f3 de les opcions terap\u00e8utiques, les noves l\u00ednies de tractament, aix\u00ed com l\u2019estat actual i perspectives futures de la recerca en esclerosi m\u00faltiple. Durant la seva intervenci\u00f3, va subratllar que \u201cel diagn\u00f2stic preco\u00e7 \u00e9s molt important per millorar el pron\u00f2stic a llarg termini\u201d.<\/strong> Actualment, l’estrat\u00e8gia terap\u00e8utica<\/strong> ha evolucionat cap a l’\u00fas de f\u00e0rmacs d\u2019alta efic\u00e0cia des de l’inici<\/strong>. Alhora, va destacar com a fita clau que l\u2019any 2023 es va aconseguir que l\u2019Organitzaci\u00f3 Mundial de la Salut (OMS) inclogu\u00e9s dins el llistat de medicaments essencials tres f\u00e0rmacs per l\u2019esclerosi m\u00faltiple.  <\/p>\n\n\n\n

\"El<\/a>
El Dr. Xavier Montalban en un moment de la seva presentaci\u00f3. <\/figcaption><\/figure>\n\n\n\n

El paper de la farm\u00e0cia en l\u2019acompanyament dels pacients<\/strong><\/h2>\n\n\n\n

L’infermer Miguel Robles<\/strong> va posar el focus en la simptomatologia associada, l\u2019acompanyament del pacient amb esclerosi m\u00faltiple, el maneig del tractament, la import\u00e0ncia de l\u2019adher\u00e8ncia terap\u00e8utica, l\u2019educaci\u00f3 sanit\u00e0ria i el suport al pacient, tot plegat acompanyat de casos pr\u00e0ctics. \u201cLa farm\u00e0cia pot detectar necessitats que la persona no sempre expressa en consulta<\/strong>. Alhora, \u00e9s un punt de proximitat, que pot refor\u00e7ar, detectar i connectar amb l\u2019equip m\u00e8dic<\/strong>\u201d, va destacar Robles.<\/p>\n\n\n\n

Tot seguit, va remarcar la import\u00e0ncia que \u201cla persona rebi missatges coherents, segurs i centrats en les seves necessitats\u201d.<\/strong> I va posar de relleu que la millor adher\u00e8ncia no \u00e9s nom\u00e9s de la persona, sin\u00f3 tamb\u00e9 de tots els membres del sistema sanitari.<\/p>\n\n\n\n

\"Miguel<\/a>
Miguel Robles durant la seva intervenci\u00f3. <\/figcaption><\/figure>\n\n\n\n

D\u2019altra banda, va detallar com actuar des de la farm\u00e0cia quan at\u00e9n un pacient durant un episodi de calor,<\/strong> ja que pot empitjorar temporalment s\u00edmptomes previs, generar alarma i confusi\u00f3 amb un brot. \u201cCal descartar s\u00edmptomes, com pres\u00e8ncia de febre o infecci\u00f3, aconsellar refredament i hidrataci\u00f3, revisar medicaci\u00f3 que pugui empitjorar s\u00edmptomes i orientar si hi ha criteris d\u2019alarma\u201d.<\/p>\n\n\n\n

El testimoni d\u2019una persona amb esclerosi m\u00faltiple<\/strong><\/h2>\n\n\n\n

La sessi\u00f3 tamb\u00e9 va comptar amb el testimoni d’Enric Riera<\/strong>, qui va compartir la seva experi\u00e8ncia convivint amb la malaltia, destacant que l\u2019activitat f\u00edsica i una actitud positiva<\/strong> s\u00f3n fonamentals per al seu benestar. Riera va agrair el paper de la farm\u00e0cia comunit\u00e0ria com a guia en el maneig de la seva medicaci\u00f3 i va explicar com l’impacte de la calor \u00e9s un dels factors m\u00e9s limitants en el seu dia a dia: “Si t\u2019excedeixes prenent el sol, despr\u00e9s no t\u2019aixeques”. Aquesta realitat refor\u00e7a la necessitat de consells farmac\u00e8utics sobre hidrataci\u00f3 i regulaci\u00f3 de la temperatura externa<\/strong>.<\/p>\n\n\n\n

\"Enric<\/a>
Enric Riera compartint el seu testimoni. <\/figcaption><\/figure>\n\n\n\n
\n\n\n\n

El COFB i la FEM col\u00b7laboren per sensibilitzar en la malaltia<\/strong><\/h2>\n\n\n\n

Aquesta confer\u00e8ncia forma part de la col\u00b7laboraci\u00f3 conjunta que han iniciat el COFB i la FEM. Tal com va explicar la directora de la FEM, Rosa Masriera<\/strong>, \u00e9s important sensibilitzar sobre el fenomen d’Uhthoff<\/strong>, segons el qual l’augment de la temperatura intensifica els s\u00edmptomes de l\u2019esclerosi m\u00faltiple. Amb aquesta confer\u00e8ncia i futures accions que duran a terme, el farmac\u00e8utic es posiciona com un agent actiu de suport<\/strong> a les persones amb aquesta malaltia.<\/p>\n\n\n\n

\"\"<\/a><\/figure>\n\n\n\n

Per la seva banda, Miquel Recasens<\/strong>, tresorer i responsable de la Comissi\u00f3 de Comprom\u00eds Social del COFB, va posar en valor que la Fundaci\u00f3 Esclerosi M\u00faltiple ha estat l’entitat seleccionada aquest 2026<\/strong> del conjunt de propostes que van arribar al COFB, a trav\u00e9s de la convocat\u00f2ria que va obrir la Comissi\u00f3 de Comprom\u00eds Social per impulsar activitats socials d\u2019\u00e0mbit sanitari.<\/p>\n\n\n\n<\/div>\n\n\n\n

<\/p>\n\n\n\n

Coorganitza:<\/strong><\/p>\n\n\n\n

\"\"<\/a><\/figure>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

El Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB) va acollir la sessi\u00f3 formativa \u201cLa farm\u00e0cia es mulla per l’esclerosi m\u00faltiple: situaci\u00f3 actual, opcions terap\u00e8utiques i casos pr\u00e0ctics\u201d, coorganitzada amb la Fundaci\u00f3 Esclerosi M\u00faltiple (FEM). La confer\u00e8ncia, moderada per Miquel Recasens, tresorer i responsable de la Comissi\u00f3 de Comprom\u00eds Social del COFB, […]<\/p>\n","protected":false},"author":3,"featured_media":84834,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[23,57],"tags":[2221,215,68,5544,5543,76],"class_list":["post-84832","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-destacats","category-mon-collegial","tag-em","tag-esclerosi-multiple","tag-farmacia","tag-fundacio-esclerosi-multiple","tag-la-farmacia-es-mulla-per-lesclerosi-multiple","tag-oficina-de-farmacia"],"yoast_head":"\nLa farm\u00e0cia es mulla per l\u2019esclerosi m\u00faltiple: situaci\u00f3 actual, opcions terap\u00e8utiques i casos pr\u00e0ctics - Col\u00b7legi de Farmac\u00e8utics de Barcelona<\/title>\n<meta name=\"description\" content=\"El Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB) va acollir la sessi\u00f3 formativa \u201cLa farm\u00e0cia es mulla per l'esclerosi m\u00faltiple: situaci\u00f3 actual, opcions terap\u00e8utiques i casos pr\u00e0ctics\u201d.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cofb.org\/ca\/2026\/05\/29\/la-farmacia-es-mulla-per-lesclerosi-multiple-situacio-actual-opcions-terapeutiques-i-casos-practics\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"La farm\u00e0cia es mulla per l\u2019esclerosi m\u00faltiple: situaci\u00f3 actual, opcions terap\u00e8utiques i casos pr\u00e0ctics - Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"og:description\" content=\"El Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB) va acollir la sessi\u00f3 formativa \u201cLa farm\u00e0cia es mulla per l'esclerosi m\u00faltiple: situaci\u00f3 actual, opcions terap\u00e8utiques i casos pr\u00e0ctics\u201d.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cofb.org\/ca\/2026\/05\/29\/la-farmacia-es-mulla-per-lesclerosi-multiple-situacio-actual-opcions-terapeutiques-i-casos-practics\/\" \/>\n<meta property=\"og:site_name\" content=\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-29T10:06:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-29T10:06:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cofb.org\/wp-content\/uploads\/2026\/05\/COFB_ESCLEROSI-MULTIPLE_29052026_1-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1440\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Berta Mart\u00ednez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:site\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"Berta Mart\u00ednez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.cofb.org\/2026\/05\/29\/la-farmacia-es-mulla-per-lesclerosi-multiple-situacio-actual-opcions-terapeutiques-i-casos-practics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/2026\/05\/29\/la-farmacia-es-mulla-per-lesclerosi-multiple-situacio-actual-opcions-terapeutiques-i-casos-practics\/\"},\"author\":{\"name\":\"Berta Mart\u00ednez\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/f32de3b41b812c85ff923cb4cc849063\"},\"headline\":\"La farm\u00e0cia es mulla per l\u2019esclerosi m\u00faltiple: situaci\u00f3 actual, opcions terap\u00e8utiques i casos pr\u00e0ctics\",\"datePublished\":\"2026-05-29T10:06:38+00:00\",\"dateModified\":\"2026-05-29T10:06:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.cofb.org\/2026\/05\/29\/la-farmacia-es-mulla-per-lesclerosi-multiple-situacio-actual-opcions-terapeutiques-i-casos-practics\/\"},\"wordCount\":823,\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/2026\/05\/29\/la-farmacia-es-mulla-per-lesclerosi-multiple-situacio-actual-opcions-terapeutiques-i-casos-practics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2026\/05\/COFB_ESCLEROSI-MULTIPLE_29052026_1-scaled.jpg\",\"keywords\":[\"EM\",\"esclerosi m\u00faltiple\",\"Farm\u00e0cia\",\"Fundaci\u00f3 Esclerosi M\u00faltiple\",\"la farm\u00e0cia es mulla per l'esclerosi m\u00faltiple\",\"Oficina de farm\u00e0cia\"],\"articleSection\":[\"Destacats\",\"M\u00f3n col\u00b7legial\"],\"inLanguage\":\"ca\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cofb.org\/2026\/05\/29\/la-farmacia-es-mulla-per-lesclerosi-multiple-situacio-actual-opcions-terapeutiques-i-casos-practics\/\",\"url\":\"https:\/\/www.cofb.org\/2026\/05\/29\/la-farmacia-es-mulla-per-lesclerosi-multiple-situacio-actual-opcions-terapeutiques-i-casos-practics\/\",\"name\":\"La farm\u00e0cia es mulla per l\u2019esclerosi m\u00faltiple: situaci\u00f3 actual, opcions terap\u00e8utiques i casos pr\u00e0ctics - Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.cofb.org\/2026\/05\/29\/la-farmacia-es-mulla-per-lesclerosi-multiple-situacio-actual-opcions-terapeutiques-i-casos-practics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/2026\/05\/29\/la-farmacia-es-mulla-per-lesclerosi-multiple-situacio-actual-opcions-terapeutiques-i-casos-practics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2026\/05\/COFB_ESCLEROSI-MULTIPLE_29052026_1-scaled.jpg\",\"datePublished\":\"2026-05-29T10:06:38+00:00\",\"dateModified\":\"2026-05-29T10:06:40+00:00\",\"description\":\"El Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB) va acollir la sessi\u00f3 formativa \u201cLa farm\u00e0cia es mulla per l'esclerosi m\u00faltiple: situaci\u00f3 actual, opcions terap\u00e8utiques i casos pr\u00e0ctics\u201d.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.cofb.org\/2026\/05\/29\/la-farmacia-es-mulla-per-lesclerosi-multiple-situacio-actual-opcions-terapeutiques-i-casos-practics\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cofb.org\/2026\/05\/29\/la-farmacia-es-mulla-per-lesclerosi-multiple-situacio-actual-opcions-terapeutiques-i-casos-practics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/2026\/05\/29\/la-farmacia-es-mulla-per-lesclerosi-multiple-situacio-actual-opcions-terapeutiques-i-casos-practics\/#primaryimage\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2026\/05\/COFB_ESCLEROSI-MULTIPLE_29052026_1-scaled.jpg\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2026\/05\/COFB_ESCLEROSI-MULTIPLE_29052026_1-scaled.jpg\",\"width\":2560,\"height\":1440,\"caption\":\"D'esquerra a dreta: Miguel Robles, el Dr. Xavier Montalban, Rosa Masriera, Miquel Recasens i Enric Riera.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cofb.org\/2026\/05\/29\/la-farmacia-es-mulla-per-lesclerosi-multiple-situacio-actual-opcions-terapeutiques-i-casos-practics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/novaorg.cofb.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"La farm\u00e0cia es mulla per l\u2019esclerosi m\u00faltiple: situaci\u00f3 actual, opcions terap\u00e8utiques i casos pr\u00e0ctics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cofb.org\/#website\",\"url\":\"https:\/\/www.cofb.org\/\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cofb.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cofb.org\/#organization\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"url\":\"https:\/\/www.cofb.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"width\":500,\"height\":105,\"caption\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\",\"https:\/\/twitter.com\/farmaceuticsbcn\",\"https:\/\/www.instagram.com\/farmaceuticsbcn\/\",\"https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/f32de3b41b812c85ff923cb4cc849063\",\"name\":\"Berta Mart\u00ednez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d4c584dab5da1ee9e3c3df161c0aabec7075cc8211cd46ffc79bfe177aa78b01?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d4c584dab5da1ee9e3c3df161c0aabec7075cc8211cd46ffc79bfe177aa78b01?s=96&d=mm&r=g\",\"caption\":\"Berta Mart\u00ednez\"},\"url\":\"https:\/\/www.cofb.org\/ca\/author\/bmartinez\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"La farm\u00e0cia es mulla per l\u2019esclerosi m\u00faltiple: situaci\u00f3 actual, opcions terap\u00e8utiques i casos pr\u00e0ctics - Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"El Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB) va acollir la sessi\u00f3 formativa \u201cLa farm\u00e0cia es mulla per l'esclerosi m\u00faltiple: situaci\u00f3 actual, opcions terap\u00e8utiques i casos pr\u00e0ctics\u201d.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cofb.org\/ca\/2026\/05\/29\/la-farmacia-es-mulla-per-lesclerosi-multiple-situacio-actual-opcions-terapeutiques-i-casos-practics\/","og_locale":"ca_ES","og_type":"article","og_title":"La farm\u00e0cia es mulla per l\u2019esclerosi m\u00faltiple: situaci\u00f3 actual, opcions terap\u00e8utiques i casos pr\u00e0ctics - Col\u00b7legi de Farmac\u00e8utics de Barcelona","og_description":"El Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB) va acollir la sessi\u00f3 formativa \u201cLa farm\u00e0cia es mulla per l'esclerosi m\u00faltiple: situaci\u00f3 actual, opcions terap\u00e8utiques i casos pr\u00e0ctics\u201d.","og_url":"https:\/\/www.cofb.org\/ca\/2026\/05\/29\/la-farmacia-es-mulla-per-lesclerosi-multiple-situacio-actual-opcions-terapeutiques-i-casos-practics\/","og_site_name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","article_publisher":"https:\/\/www.facebook.com\/farmaceuticsbcn\/","article_published_time":"2026-05-29T10:06:38+00:00","article_modified_time":"2026-05-29T10:06:40+00:00","og_image":[{"width":2560,"height":1440,"url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2026\/05\/COFB_ESCLEROSI-MULTIPLE_29052026_1-scaled.jpg","type":"image\/jpeg"}],"author":"Berta Mart\u00ednez","twitter_card":"summary_large_image","twitter_creator":"@farmaceuticsbcn","twitter_site":"@farmaceuticsbcn","twitter_misc":{"Escrit per":"Berta Mart\u00ednez","Temps estimat de lectura":"6 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.cofb.org\/2026\/05\/29\/la-farmacia-es-mulla-per-lesclerosi-multiple-situacio-actual-opcions-terapeutiques-i-casos-practics\/#article","isPartOf":{"@id":"https:\/\/www.cofb.org\/2026\/05\/29\/la-farmacia-es-mulla-per-lesclerosi-multiple-situacio-actual-opcions-terapeutiques-i-casos-practics\/"},"author":{"name":"Berta Mart\u00ednez","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/f32de3b41b812c85ff923cb4cc849063"},"headline":"La farm\u00e0cia es mulla per l\u2019esclerosi m\u00faltiple: situaci\u00f3 actual, opcions terap\u00e8utiques i casos pr\u00e0ctics","datePublished":"2026-05-29T10:06:38+00:00","dateModified":"2026-05-29T10:06:40+00:00","mainEntityOfPage":{"@id":"https:\/\/www.cofb.org\/2026\/05\/29\/la-farmacia-es-mulla-per-lesclerosi-multiple-situacio-actual-opcions-terapeutiques-i-casos-practics\/"},"wordCount":823,"publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"image":{"@id":"https:\/\/www.cofb.org\/2026\/05\/29\/la-farmacia-es-mulla-per-lesclerosi-multiple-situacio-actual-opcions-terapeutiques-i-casos-practics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2026\/05\/COFB_ESCLEROSI-MULTIPLE_29052026_1-scaled.jpg","keywords":["EM","esclerosi m\u00faltiple","Farm\u00e0cia","Fundaci\u00f3 Esclerosi M\u00faltiple","la farm\u00e0cia es mulla per l'esclerosi m\u00faltiple","Oficina de farm\u00e0cia"],"articleSection":["Destacats","M\u00f3n col\u00b7legial"],"inLanguage":"ca"},{"@type":"WebPage","@id":"https:\/\/www.cofb.org\/2026\/05\/29\/la-farmacia-es-mulla-per-lesclerosi-multiple-situacio-actual-opcions-terapeutiques-i-casos-practics\/","url":"https:\/\/www.cofb.org\/2026\/05\/29\/la-farmacia-es-mulla-per-lesclerosi-multiple-situacio-actual-opcions-terapeutiques-i-casos-practics\/","name":"La farm\u00e0cia es mulla per l\u2019esclerosi m\u00faltiple: situaci\u00f3 actual, opcions terap\u00e8utiques i casos pr\u00e0ctics - Col\u00b7legi de Farmac\u00e8utics de Barcelona","isPartOf":{"@id":"https:\/\/www.cofb.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cofb.org\/2026\/05\/29\/la-farmacia-es-mulla-per-lesclerosi-multiple-situacio-actual-opcions-terapeutiques-i-casos-practics\/#primaryimage"},"image":{"@id":"https:\/\/www.cofb.org\/2026\/05\/29\/la-farmacia-es-mulla-per-lesclerosi-multiple-situacio-actual-opcions-terapeutiques-i-casos-practics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2026\/05\/COFB_ESCLEROSI-MULTIPLE_29052026_1-scaled.jpg","datePublished":"2026-05-29T10:06:38+00:00","dateModified":"2026-05-29T10:06:40+00:00","description":"El Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB) va acollir la sessi\u00f3 formativa \u201cLa farm\u00e0cia es mulla per l'esclerosi m\u00faltiple: situaci\u00f3 actual, opcions terap\u00e8utiques i casos pr\u00e0ctics\u201d.","breadcrumb":{"@id":"https:\/\/www.cofb.org\/2026\/05\/29\/la-farmacia-es-mulla-per-lesclerosi-multiple-situacio-actual-opcions-terapeutiques-i-casos-practics\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cofb.org\/2026\/05\/29\/la-farmacia-es-mulla-per-lesclerosi-multiple-situacio-actual-opcions-terapeutiques-i-casos-practics\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/2026\/05\/29\/la-farmacia-es-mulla-per-lesclerosi-multiple-situacio-actual-opcions-terapeutiques-i-casos-practics\/#primaryimage","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2026\/05\/COFB_ESCLEROSI-MULTIPLE_29052026_1-scaled.jpg","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2026\/05\/COFB_ESCLEROSI-MULTIPLE_29052026_1-scaled.jpg","width":2560,"height":1440,"caption":"D'esquerra a dreta: Miguel Robles, el Dr. Xavier Montalban, Rosa Masriera, Miquel Recasens i Enric Riera."},{"@type":"BreadcrumbList","@id":"https:\/\/www.cofb.org\/2026\/05\/29\/la-farmacia-es-mulla-per-lesclerosi-multiple-situacio-actual-opcions-terapeutiques-i-casos-practics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/novaorg.cofb.net\/"},{"@type":"ListItem","position":2,"name":"La farm\u00e0cia es mulla per l\u2019esclerosi m\u00faltiple: situaci\u00f3 actual, opcions terap\u00e8utiques i casos pr\u00e0ctics"}]},{"@type":"WebSite","@id":"https:\/\/www.cofb.org\/#website","url":"https:\/\/www.cofb.org\/","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"","publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cofb.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/www.cofb.org\/#organization","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","url":"https:\/\/www.cofb.org\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","width":500,"height":105,"caption":"Col\u00b7legi de Farmac\u00e8utics de Barcelona"},"image":{"@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/farmaceuticsbcn\/","https:\/\/twitter.com\/farmaceuticsbcn","https:\/\/www.instagram.com\/farmaceuticsbcn\/","https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/"]},{"@type":"Person","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/f32de3b41b812c85ff923cb4cc849063","name":"Berta Mart\u00ednez","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d4c584dab5da1ee9e3c3df161c0aabec7075cc8211cd46ffc79bfe177aa78b01?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d4c584dab5da1ee9e3c3df161c0aabec7075cc8211cd46ffc79bfe177aa78b01?s=96&d=mm&r=g","caption":"Berta Mart\u00ednez"},"url":"https:\/\/www.cofb.org\/ca\/author\/bmartinez\/"}]}},"uagb_featured_image_src":{"full":["https:\/\/www.cofb.org\/wp-content\/uploads\/2026\/05\/COFB_ESCLEROSI-MULTIPLE_29052026_1-scaled.jpg",2560,1440,false],"thumbnail":["https:\/\/www.cofb.org\/wp-content\/uploads\/2026\/05\/COFB_ESCLEROSI-MULTIPLE_29052026_1-150x150.jpg",150,150,true],"medium":["https:\/\/www.cofb.org\/wp-content\/uploads\/2026\/05\/COFB_ESCLEROSI-MULTIPLE_29052026_1-300x169.jpg",300,169,true],"medium_large":["https:\/\/www.cofb.org\/wp-content\/uploads\/2026\/05\/COFB_ESCLEROSI-MULTIPLE_29052026_1-768x432.jpg",768,432,true],"large":["https:\/\/www.cofb.org\/wp-content\/uploads\/2026\/05\/COFB_ESCLEROSI-MULTIPLE_29052026_1-1024x576.jpg",1024,576,true],"1536x1536":["https:\/\/www.cofb.org\/wp-content\/uploads\/2026\/05\/COFB_ESCLEROSI-MULTIPLE_29052026_1-1536x864.jpg",1536,864,true],"2048x2048":["https:\/\/www.cofb.org\/wp-content\/uploads\/2026\/05\/COFB_ESCLEROSI-MULTIPLE_29052026_1-2048x1152.jpg",2048,1152,true],"trp-custom-language-flag":["https:\/\/www.cofb.org\/wp-content\/uploads\/2026\/05\/COFB_ESCLEROSI-MULTIPLE_29052026_1-18x10.jpg",18,10,true]},"uagb_author_info":{"display_name":"Berta Mart\u00ednez","author_link":"https:\/\/www.cofb.org\/ca\/author\/bmartinez\/"},"uagb_comment_info":0,"uagb_excerpt":"El Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB) va acollir la sessi\u00f3 formativa \u201cLa farm\u00e0cia es mulla per l’esclerosi m\u00faltiple: situaci\u00f3 actual, opcions terap\u00e8utiques i casos pr\u00e0ctics\u201d, coorganitzada amb la Fundaci\u00f3 Esclerosi M\u00faltiple (FEM). La confer\u00e8ncia, moderada per Miquel Recasens, tresorer i responsable de la Comissi\u00f3 de Comprom\u00eds Social del COFB, […]","_links":{"self":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/84832","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/comments?post=84832"}],"version-history":[{"count":5,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/84832\/revisions"}],"predecessor-version":[{"id":84843,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/84832\/revisions\/84843"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/media\/84834"}],"wp:attachment":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/media?parent=84832"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/categories?post=84832"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/tags?post=84832"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}